The report “Nerve Repair and Regeneration Market by Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy, Neurostimulation Surgery), Products (Biomaterials, Nerve Conduits, Nerve Protectors, Nerve Wraps, Neurostimulation Devices) – Global Forecast to 2022″, The nerve repair and regeneration market is expected to reach USD 10.59 Billion by 2022 from USD 5.79 Billion in 2017, at a CAGR of 12.9%. Increasing number of neurological disorders, rising geriatric population, and technological advancements are the major factors that are driving the growth of this market.
The nerve repair and regeneration market is segmented on the basis of product, application, and end user. The internal neurostimulation device market is subsegmented into spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electrical stimulation. The spinal cord stimulation segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to increasing number of spinal cord injuries.
Based on nerve graft, the nerve repair and regeneration market is subsegmented into autograft, allograft, and xenograft. In 2017, the autograft segment is expected to account for the largest share of the market. This is because of short recovery time and technological advancement.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=883
By region, the nerve repair and regeneration market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, however, the Asian region is expected to witness the highest growth during the forecast period. The presence of emerging economies like China and India; large population; growth in the number of hospitals, and increasing neurological disorders in the region are some of the key factors driving the high growth of this regional segment.
Some of the major players operating in the nerve repair and regeneration market are AxoGen (US), Baxter (US), Boston Scientific (US), LivaNova (UK), Integra LifeSciences (US), Medtronic (US), Abbott Laboratories (US), Stryker (US), Nevro (US), Polyganics (Netherlands), and Nuvectra (US).